Research Paper Volume 15, Issue 19 pp 10732—10745

Micheliolide prevents estrogen deficiency-induced bone loss via inhibiting osteoclast bone resorption

Ziyang Gan1, *, , Junming Huang1,2, *, , Mingyou Xu1, *, , Xingshi Yuan1, , Xifu Shang1, , Xi Chen1, , Kun Chen1, ,

  • 1 Department of Orthopedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, Anhui, China
  • 2 Department of Orthopedics, The First Affiliated Hospital of Nanchang University, Nanchang 330000, Jiangxi, China
* Equal contribution

Received: March 23, 2023       Accepted: September 18, 2023       Published: October 11, 2023
How to Cite

Copyright: © 2023 Gan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Osteoporosis is one of the major health problems characterized by decreased bone density and increased risk of fractures. Nowadays, the treating strategies against osteoporosis are efficient, but still have some drawbacks. Micheliolide, a guaianolide sesquiterpene lactone isolated from Michelia compressa and Michelia champac, has been reported to have anti-inflammatory effects. Here, our data suggest that Micheliolide could protect mice from ovariectomy induced bone loss. According to the Micro-CT scan and histomorphometry quantification data, Micheliolide treatment inhibits excessive osteoclast bone resorption without affecting bone formation in estrogen deficiency mice. Consistently, our data suggest that Micheliolide could inhibit osteoclastogenesis in vitro. Additionally, we confirmed that Micheliolide inhibits osteoclasts formation via inhibiting P38 MAPK signaling pathway, and P79350 (a P38 agonist) could rescue this effect. In summary, our data suggest that Micheliolide could ameliorate estrogen deficiency-induced bone loss via attenuating osteoclastogenesis. Hence, Micheliolide could be used as a novel anti-resorptive agent against osteoporosis.


OVX: Ovariectomy; M-CSF: macrophage colony-stimulating factor; RANKL: receptor activator of NF-κB ligand; TRAP: Tartrate resistant acid phosphatase; BV/TV: bone volume/tissue volume; Tb.N: trabecular number; Tb.Th: trabecular thickness; Tb.Sp: trabecular separation; N.Oc/BS: number of osteoclasts normalized to the bone surface; Oc.S/BS: surface area of osteoclast to bone surface area; BMD: Bone mineral density; N.Ob/BS: number of osteoblasts normalized to the bone surface; Ob.S/BS: surface area of osteoblast to bone surface area; BFR/BS: bone formation rate; MAR: mineral apposition rate; SMI: structure model index.